Compare NTRA & KGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | KGC |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 32.7B |
| IPO Year | 2015 | N/A |
| Metric | NTRA | KGC |
|---|---|---|
| Price | $244.06 | $27.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $227.69 | $28.80 |
| AVG Volume (30 Days) | 1.7M | ★ 8.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 0.46% |
| EPS Growth | N/A | ★ 137.72 |
| EPS | N/A | ★ 1.43 |
| Revenue | $2,116,676,000.00 | ★ $6,443,900,000.00 |
| Revenue This Year | $32.77 | $38.87 |
| Revenue Next Year | $16.51 | $16.85 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | ★ 38.17 | 32.90 |
| 52 Week Low | $125.38 | $9.00 |
| 52 Week High | $245.59 | $28.81 |
| Indicator | NTRA | KGC |
|---|---|---|
| Relative Strength Index (RSI) | 80.03 | 59.12 |
| Support Level | $233.67 | $26.70 |
| Resistance Level | $240.18 | $28.81 |
| Average True Range (ATR) | 7.39 | 1.04 |
| MACD | 0.68 | 0.13 |
| Stochastic Oscillator | 97.49 | 68.75 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Kinross Gold is a Canada-based gold producer, producing roughly 2.1 million gold equivalent ounces in 2024. The company had about a decade of gold reserves at the end of 2024. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. Kinross has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada. If developed as we think likely, it could produce an average of more than 500,000 ounces of gold per year for at least a decade, with its unit cash costs likely in the first quartile of the industry cost curve. Though Great Bear's production is likely to be replacement ounces for falling volumes at other mines.